Richard L. Momparler

Formation

• B. Sc. en zoologie et chimie, Michigan State University (1957)
• Ph. D. en pharmacologie, Université du Vermont (1964)
• Stages postdoctoraux :
  • Yale University (1964-1965)
  • International Laboratory of Genetics and Biophysics, Naples, Italie (1966)

Thèmes de recherche du laboratoire

• Évaluation des médicaments anticancéreux
• Méthylation d’ADN et cancer
• Thérapie épigénétique du cancer

Membres du laboratoire

• Côté, Sylvie, Ph.D., assistant de recherché
• Fernandes, Samia, Ph.D., postdoctorante
• Farley-Momparler, Louise, technicienne de laboratoire

Publications récentes

• Momparler RL, Côté S. Targeting cancer stem cells by inhibitors of DNA and histone methylation.
• Expert Opinion Investigational Drugs 2015; 24(8): 1-13.
• Stephan L, Momparler RL. Combination chemotherapy of cancer using the inhibitor of DNA methylation 5-aza-‐2’‐deoxycytidine (decitabine). J Cancer Res Ther 2015 (in press).
• Momparler RL, Côté S, Momparler LF, Idaghdour Y. Epigenetic therapy of acute myeloid leukemia using 5-aza-2′-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenetics. 2014;6(1):19.
• Momparler RL. Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.
• Exp Hematol Oncol. 2013; 2(1):20.
• Momparler RL, Idaghdour Y, Marquez VE, Momparler LF. Synergistic antileukemic action  of inhibitors of DNA methylation and histone methylation. Leukemia Res 2012; 36: 1049-1054.
• Momparler RL. A Perspective on the comparison of antileukemic activity of  5-aza-2′-deoxycytidine (Decitabine) and 5-azacytidine (Vidaza). Pharmaceuticals 2012; 5: 875-881.